Acute Decompensated Heart Failure with Severe Left Ventricular Systolic Dysfunction of Undetermined Etiology in a 26-Year-Old Male: A Case Report
Downloads
DOI:
https://doi.org/10.71079/ASIDE.CV.081826789Abstract
Heart failure with reduced ejection fraction HFrEF is rare in young adults but may develop when multiple uncontrolled cardiovascular risk factors are present. The diagnosis of an underlying cause of heart failure among younger patients is difficult due to multiple possible etiologies of LV systolic dysfunction, which might have similar clinical manifestations and imaging features. A 26-year-old man with a past medical history of uncontrolled hypertension and smoking, who came to hospital with complaints of sudden onset of dyspnea and chest pain on the left side, was investigated further to have sinus tachycardia with abnormal R-wave progression on electrocardiogram, cardiomegaly with pulmonary congestion on chest X-ray, and significantly impaired global systolic function of the left ventricle with ejection fraction of 25% on transthoracic echocardiogram. Troponins showed no dynamic change in their rise-and-fall pattern, ruling out acute coronary syndrome. He was stabilized on CPAP breathing and IV nitroglycerine and loop diuretics, with marked relief in symptoms. Following hemodynamic stabilization, guideline-directed medical therapy for HFrEF was initiated. In this case, there is acute decompensated heart failure with reduced ejection fraction (HFrEF) characterized by severe systolic dysfunction occurring in a relatively young individual suffering from numerous risk factors for cardiovascular disorders. The etiology of the condition could not be precisely determined due to the unavailability of coronary angiography and other advanced diagnostic methods. Ischemic cardiomyopathy is just one of the potential causes that also include hypertensive cardiomyopathy, idiopathic dilated cardiomyopathy, toxic cardiomyopathy, and inflammatory cardiomyopathy. The present report highlights the need for careful etiologic assessment of patients presenting with recently developed ventricular dysfunction, appropriate diagnosis in the absence of evidence of coronary disease, and prompt initiation of appropriate therapy
Keywords:
Heart failure with reduced ejection fraction, Undetermined etiology cardiomyopathy, Ischemic cardiomyopathy, Acute pulmonary edema, Hypertension中文摘要
26岁男性病因不明的急性失代偿性心力衰竭伴严重左室收缩功能障碍:病例报告
射血分数降低的心力衰竭(HFrEF)在年轻成人中较为罕见,但当多种未控制的心血管危险因素同时存在时,可能会发生。由于左室收缩功能障碍的多种可能病因可能表现出相似的临床症状和影像特征,年轻患者中确诊心力衰竭的根本原因具有挑战性。26岁男性,既往有高血压未控制及吸烟史,因突发呼吸困难及左侧胸痛入院。进一步检查显示心电图出现窦性心动过速并伴有R波进展异常,胸片显示心脏肥大伴肺充血,超声心动图显示左室整体收缩功能显著受损,射血分数仅为25%。肌钙蛋白未出现上升-下降的动态变化,排除急性冠脉综合征。患者在CPAP呼吸、静脉硝酸甘油及袢利尿剂支持下稳定,症状明显缓解。血流动力学稳定后,按指南启动HFrEF的药物治疗。该病例表现为急性失代偿性心力衰竭伴严重收缩功能障碍,发生于相对年轻、具有多种心血管危险因素的个体。由于缺乏冠状动脉造影及其他先进诊断手段,病因未能精确确定。缺血性心肌病仅是潜在原因之一,其他可能包括高血压性心肌病、特发性扩张型心肌病、毒性心肌病及炎性心肌病。本报告强调在出现新近发作的心室功能障碍时,需要仔细评估病因,在无冠脉疾病证据的情况下做出适当诊断,并及时启动相应治疗。
本中文摘要为机器辅助翻译,仅供参考;以英文摘要为准。 Machine-assisted Chinese translation of the English abstract; the English abstract is the version of record.
References
1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11. [doi:10.15420/cfr.2016:25:2].
2. Tsao C, Aday A, Almarzooq Z, others. Heart disease and stroke statistics---2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. [doi:10.1161/CIR.0000000000001123].
3. McDonagh T, Metra M, Adamo M, others. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. [doi:10.1093/eurheartj/ehab368].
4. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39(2):210-8. [doi:10.1016/s0735-1097(01)01738-7].
5. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97(3):282-9. [doi:10.1161/01.cir.97.3.282].
6. Sharma S, Makkar J, Bana A, others. Premature coronary artery disease, risk factors, clinical presentation, angiography and interventions: hospital-based registry. Indian Heart J. 2022;74(5):391-7. [doi:10.1016/j.ihj.2022.08.003].
7. Smith C, Seigerman M, Adusumalli S, others. Evolution and outcomes of premature coronary artery disease. Curr Cardiol Rep. 2021;23(4):36. [doi:10.1007/s11886-021-01457-8].
8. Yusuf S, Hawken S, Ounpuu S, INTERHEART Study I, others. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries: case-control study. Lancet. 2004;364(9438):937-52. [doi:10.1016/S0140-6736(04)17018-9].
9. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53(7):557-73. [doi:10.1016/j.jacc.2008.10.041].
10. Milne EN, Pistolesi M, Miniati M, Giuntini C. The radiologic distinction of cardiogenic and noncardiogenic edema. AJR Am J Roentgenol. 1985;144(5):879-94. [doi:10.2214/ajr.144.5.879].
11. Lang R, Bierig M, Devereux R, American Society of E, others. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79-108. [doi:10.1016/j.euje.2005.12.014].
12. Yancy C, Jessup M, Bozkurt B, others. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation. 2017;136(6):e137-61. [doi:10.1161/CIR.0000000000000509].
13. McMurray J, Packer M, Desai A, PARADIGM-HF I, others. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. [doi:10.1056/NEJMoa1409077].
14. Packer M, Anker S, Butler J, EMPEROR-Reduced Trial I, others. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-24. [doi:10.1056/NEJMoa2022190].
Data Availability Statement
Data are available from the corresponding author on request.
License
Copyright (c) 2026 Abdul Eizad Asif, Ahmad Mustafa Butt, Syed Tahir Hussain, Aqsa Ibrahim, Muhammad Hassaan Javaid

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright and Licensing
All articles published in ASIDE Cardiovascular are open access and freely available online immediately upon publication, without embargo.
This journal applies the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, anyone may copy, redistribute, remix, transform, and build upon the material for any purpose, even commercially, provided that proper credit is given to the original author(s), a link to the license is provided, and any changes made are indicated.
-
License link: https://creativecommons.org/licenses/by/4.0/
-
Machine-readable license metadata is embedded in each article and its DOI record.
Copyright Holder
Copyright in all articles remains with the author(s). ASIDE Cardiovascular is published and owned by PubPorta Publishing LLC. By submitting a manuscript, authors agree to grant the publisher a non-exclusive license to publish, distribute, archive, and identify itself as the original publisher of the work under the terms of the CC BY 4.0 license.
Academic oversight and scholarly guidance are provided by the American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE). Copyright and licensing arrangements are administered by the publisher.
Third-party Material
Any material (e.g., images, figures, or tables) not covered by CC BY 4.0 will be clearly indicated in the article. Users must obtain permission directly from the copyright holder for reuse of such third-party material.
Author Rights and Self-Archiving
Authors are permitted to deposit all versions of their work (preprint, author’s accepted manuscript, and version of record) in institutional or subject repositories of their choice immediately upon publication, without embargo, provided that the DOI and license information are included.
Downloads
Published
Issue
Section
How to Cite
Article history
- Received
- 23 Apr 2026
- Received in revised form
- 8 Jun 2026
- Accepted
- 30 Jun 2026
- Published
- 18 Aug 2026